Fegert JM, Kölch M, Zito JM, Glaeske G, Janhsen K (2006). “Antidepressant use in children and adolescents in Germany”. J. Child Adolesc. Psychopharmacol.16 (1-2): 197-206. doi:10.1089/cap.2006.16.197. PMID16553540.
Laakmann G, Schüle C, Baghai T, Kieser M (1998). “St. John's wort in mild to moderate depression: the relevance of hyperforin for the clinical efficacy”. Pharmacopsychiatry31 Suppl 1: 54-59. doi:10.1055/s-2007-979346. PMID9684948.
Umek A, Kreft S, Kartnig T, Heydel B (1999). “Quantitative phytochemical analyses of six hypericum species growing in Slovenia”. Planta medica65 (4): 388-390. doi:10.1055/s-2006-960798. PMID17260265.
Tatsis EC, Boeren S, Exarchou V, Troganis AN, Vervoort J, Gerothanassis IP, (2007). “Identification of the major constituents of Hypericum perforatum by LC/SPE/NMR and/or LC/MS.”. Phytochemistry68 (3): 383-393. doi:10.1016/j.phytochem.2006.11.026. PMID17196625.
Schwob I, Bessière JM, Viano J (2002). “Composition of the essential oils of Hypericum perforatum L. from southeastern France”. C. R. Biol.325 (7): 781-785. doi:10.1016/S1631-0691(02)01489-0. PMID12360846.
Leuner K, Kazanski V, Müller M, Essin K, Henke B, Gollasch M, Harteneck C, Müller WE (2007). “Hyperforin--a key constituent of St. John's wort specifically activates TRPC6 channels”. FASEB J.21 (14): 4101-4111. doi:10.1096/fj.07-8110com. PMID1766645.
Nahrstedt A, Butterweck V (1997). “Biologically active and other chemical constituents of the herb of Hypericum perforatum L.”. Pharmacopsychiatry30 Suppl 2: 129-134. doi:10.1055/s-2007-979533. PMID9342774.
Chatterjee SS, Bhattacharya SK, Wonnemann M, Singer A, Müller WE (1998). “Hyperforin as a possible antidepressant component of hypericum extracts”. Life Sci.63 (6): 499-510. doi:10.1016/S0024-3205(98)00299-9. PMID9718074.
Chatterjee SS, Nöldner M, Koch E, Erdelmeier C (1998). “Antidepressant activity of hypericum perforatum and hyperforin: the neglected possibility”. Pharmacopsychiatry31 Suppl 1: 7-15. doi:10.1055/s-2007-979340. PMID9684942.
Schrader E (2000). “Equivalence of St John's wort extract (Ze 117) and fluoxetine: a randomized, controlled study in mild-moderate depression”. Int. Clin. Psychopharmacol.15 (2): 61-68. doi:10.1097/00004850-200015020-00001. PMID10759336.
Ernst E, Rand JI, Barnes J, Stevinson C (1998). “Adverse effects profile of the herbal antidepressant St. John's wort (Hypericum perforatum L.)”. Eur. J. Clin. Pharmacol.54 (8): 589-594. doi:10.1007/s002280050519. PMID9860144.
Fegert JM, Kölch M, Zito JM, Glaeske G, Janhsen K (2006). “Antidepressant use in children and adolescents in Germany”. J. Child Adolesc. Psychopharmacol.16 (1-2): 197-206. doi:10.1089/cap.2006.16.197. PMID16553540.
Kim HL, Streltzer J, Goebert D (1999). “St. John's wort for depression: a meta-analysis of well-defined clinical trials”. J. Nerv. Ment. Dis.187 (9): 532-538. PMID10496508.
Laakmann G, Schüle C, Baghai T, Kieser M (1998). “St. John's wort in mild to moderate depression: the relevance of hyperforin for the clinical efficacy”. Pharmacopsychiatry31 Suppl 1: 54-59. doi:10.1055/s-2007-979346. PMID9684948.
Harrer G, Schmidt U, Kuhn U, Biller A (1999). “Comparison of equivalence between the St. John's wort extract LoHyp-57 and fluoxetine”. Arzneimittelforschung.49 (4): 289-296. PMID10337446.
Umek A, Kreft S, Kartnig T, Heydel B (1999). “Quantitative phytochemical analyses of six hypericum species growing in Slovenia”. Planta medica65 (4): 388-390. doi:10.1055/s-2006-960798. PMID17260265.
Tatsis EC, Boeren S, Exarchou V, Troganis AN, Vervoort J, Gerothanassis IP, (2007). “Identification of the major constituents of Hypericum perforatum by LC/SPE/NMR and/or LC/MS.”. Phytochemistry68 (3): 383-393. doi:10.1016/j.phytochem.2006.11.026. PMID17196625.
Schwob I, Bessière JM, Viano J (2002). “Composition of the essential oils of Hypericum perforatum L. from southeastern France”. C. R. Biol.325 (7): 781-785. doi:10.1016/S1631-0691(02)01489-0. PMID12360846.
Leuner K, Kazanski V, Müller M, Essin K, Henke B, Gollasch M, Harteneck C, Müller WE (2007). “Hyperforin--a key constituent of St. John's wort specifically activates TRPC6 channels”. FASEB J.21 (14): 4101-4111. doi:10.1096/fj.07-8110com. PMID1766645.
Nahrstedt A, Butterweck V (1997). “Biologically active and other chemical constituents of the herb of Hypericum perforatum L.”. Pharmacopsychiatry30 Suppl 2: 129-134. doi:10.1055/s-2007-979533. PMID9342774.
Chatterjee SS, Bhattacharya SK, Wonnemann M, Singer A, Müller WE (1998). “Hyperforin as a possible antidepressant component of hypericum extracts”. Life Sci.63 (6): 499-510. doi:10.1016/S0024-3205(98)00299-9. PMID9718074.
Chatterjee SS, Nöldner M, Koch E, Erdelmeier C (1998). “Antidepressant activity of hypericum perforatum and hyperforin: the neglected possibility”. Pharmacopsychiatry31 Suppl 1: 7-15. doi:10.1055/s-2007-979340. PMID9684942.
Schrader E (2000). “Equivalence of St John's wort extract (Ze 117) and fluoxetine: a randomized, controlled study in mild-moderate depression”. Int. Clin. Psychopharmacol.15 (2): 61-68. doi:10.1097/00004850-200015020-00001. PMID10759336.
Ernst E, Rand JI, Barnes J, Stevinson C (1998). “Adverse effects profile of the herbal antidepressant St. John's wort (Hypericum perforatum L.)”. Eur. J. Clin. Pharmacol.54 (8): 589-594. doi:10.1007/s002280050519. PMID9860144.